osmotic gradients generated by active transport systems for bile salts and other organic anions, located at the basolateral and canalicular membranes. The major determinant of canalicular bile formation is the excretion of bile salts into the canaliculus ('bile saltdependent' bile flow). Canalicular excretion of reduced glutathione (GSH) and bicarbonate (HCO 3 -) constitute the major components of the 'bile salt-independent' fraction of bile flow, although the contribution of HCO 3 -occurs mainly at the level of bile duct epithelial cells (cholangiocytes), particularly when stimulated by hormones and neuropeptides (e.g. secretin, vasoactive intestinal peptide). 2 Normal bile secretion depends on: (i) active transmembrane transport systems generating the osmotic gradients for bile flow; [3] [4] [5] [6] [7] (ii) an intact cytoskeleton required for the movement of vesicles and bile canalicular contractions; (iii) cell contacts sealing off the bile canaliculi and maintaining cell polarity; and (iv) signal transduction mechanisms regulating and coordinating the various processes involved in bile formation (Fig. 1) .
The hepatocyte is a polarized epithelial cell with basolateral (sinusoidal) and apical (canalicular) plasma membrane domains. Hepatic uptake of biliary constituents (and their precursors) occurs at the basolateral membrane, which is in contact with sinusoidal blood via the space of Disse. A Na + -dependent Na + /taurocholate cotransporter (NTCP) is the main uptake system for bile salts, 8, 9 while a growing family of Na + -independent organic anion transporting proteins Recent advances in molecular biology lead to the understanding of various genetic liver diseases. The identification of the genes responsible for these disorders has especially enabled us to understand better the basic physiology of hepatic transport systems. At present, the pathophysiology of diseases affecting the liver, such as Wilson's disease, progressive familial cholestasis syndromes, and Dubin-Johnson syndrome, has become much clearer. However, better understanding also means new questions and new unresolved mysteries. In particular, in the broader sense, the question arises whether slight or moderate inherited or acquired functional impairments in hepatic transport systems are cofactors for common liver diseases including alcoholic and nonalcoholic steatohepatitis, drug-induced cholestasis or primary biliary cirrhosis. In this review we discuss two major hepatic transport systems: biliary secretion and hepatic copper metabolism in the context of normal physiology and of inherited defects of these systems.
(OATP) transports not only bile salts, but also a large variety of other (non-bile salt) organic anions (e.g. bilirubin, estrogen conjugates) and various cationic drugs. 10, 11 ( Fig. 2 ) Basolateral bile salt transport systems are essential for bile formation since approximately 95% of bile salts excreted by the liver are reabsorbed on each pass through the intestine, mainly in the terminal ileum via an apical Na + -dependent bile salt transporter (ASBT) structurally related to NTCP, 12, 13 and are returned to the liver. 1 ASBT is also expressed in bile ducts and proximal kidney tubules. Na + -dependent bile salt transport via NTCP is driven by a Na + -K + -ATPase which generates an inwardly directed Na ± gradient.
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In contrast to NTCP, OATP may function as bile salt exchangers with GSH and HCO 3 -. 11 In human liver, OATP2 [14] [15] [16] [17] and OATP8 17 are the major representatives of the OATP family. In addition, the basolateral membrane also contains members of the organic cation transporter (OCT) and organic anion transporter (OAT) families.
Canalicular bile secretion is the rate limiting step of bile formation. 18 The canalicular membrane contains both adenosine triphosphate (ATP)-dependent and ATP-independent transport systems (Fig. 2) .
3-7 ATPdependent transport systems (also known as ATPbinding cassette (ABC) proteins) transport biliary constituents against steep concentration gradients across the canalicular membrane. Most canalicular ABC proteins belong to the multidrug resistance protein (MDR) or multidrug resistance-associated protein (MRP) gene superfamily. 18 A multidrug export pump (MDR1) excretes hydrophobic cationic compounds (e.g. anticancer drugs, calcium channel blockers, cyclosporine A), 19, 20 while a phospholipid export pump (MDR3) acts as a phospolipid flippase for phosphatidylcholine. 21, 22 In addition to biliary excretion of phospholipids, bile is also a major pathway for elimination of cholesterol, which is mostly derived from plasma high-density lipoprotein (HDL). Hepatocellular uptake of HDL cholesterol is mediated via a scavenger receptor (SR-BI), [23] [24] [25] while no canalicular cholesterol transporter has been identified so far.
A (bilirubin) conjugate export pump (MRP2), 26, 27 functionally also known as the canalicular multispecific organic anion transporter (cMOAT), mediates the canalicular excretion of a broad range of organic anions, most of which are conjugates with glutathione, glucuronate and sulfate formed by phase II conjugation in the hepatocyte (e.g. bilirubin diglucuronide). 28 Canalicular excretion of GSH is also mediated through MRP2. 28 Other MRP isoforms, such as MRP1 and 
MRP3
OA-, BS - Figure 2 Hepatobiliary transport systems in human liver. A Na + /taurocholate cotransporter (NTCP) at the basolateral membrane of hepatocytes mediates bile salt (BS -) uptake, while a family of Na + -independent organic anion transporting polypeptides (OATP) transports not only bile salts (BS -), but also various (non-bile salt) organic anions (OA -) and cations (OC + ). Bile salts are excreted via a canalicular bile salt export pump (BSEP), while glutathione (GSH) and (non-bile salt) organic anions (e.g. conjugated bilirubin) are excreted via a canalicular conjugate export pump (MRP2, also known as canalicular multispecific organic anion transporter, cMOAT). In addition, the canalicular membrane contains a P-type ATPase (FIC1) for aminophospholipids (PE, phosphatidyl-ethanolamine; PS, phosphatidylserine), a multidrug export pump (MDR1) for organic cations, and a phospholipid export pump (MDR3) for phosphatidylcholine (PC). Bile duct epithelial cells contain the cystic fibrosis transmembrane conductance regulator (CFTR) which is a Cl -channel driving HCO 3 -excretion via a Cl -/HCO 3 -anion exchanger (AE2). In addition, they contain the apical Na + -dependent bile salt transporter (ASBT) and MRP3 for reabsorption and cholehepatic cycling of bile salts.
MRP3, are located on the basolateral membrane where they may serve as a compensatory overflow system under cholestatic conditions with impaired canalicular (MRP2) excretory function. [29] [30] [31] A bile salt export pump (BSEP) excretes monovalent bile salts. [32] [33] [34] A P-type ATPase (FIC1, mutated in 'familial intrahepatic cholestasis') belongs to a family of aminophospholipid transporters and has also been localized to the canalicular membrane and the bile duct epithelium. 35 The detailed function of FIC1 is unclear, but mutations of this transporter result in variants of familial intrahepatic cholestasis (see below), suggesting that it must play an important direct or indirect role in canalicular bile salt excretion. 36 Strong expression of FIC1 in extrahepatic tissues such as pancreas, small intestine and kidney suggests a more general role in the regulation of secretory processes and may explain some of the extrahepatic features associated with these syndromes (e.g. pancreatitis, diarrhea, nephrolithiasis). 35, 36 In addition to ATP-dependent transport systems, the canalicular membrane also contains ATP-independent transport systems. Canalicular bicarbonate secretion is mediated via a Cl -/HCO 3 -exchanger belonging to a family of anion exchangers (AE 1-3). Anion exchanger 2 (AE2) is present in various tissues, including the liver where it is localized to both bile canaliculi and bile ducts. 37 Anion exchanger 2 and MRP2 are the major driving forces for bile salt-independent bile flow, while BSEP drives bile salt-dependent flow.
Although contributing to only 3-5% of the total liver cell mass, bile duct epithelilal cells play an important role in normal bile secretion.
1,2 Large and medium size but not small (< 40 mm in diameter) intrahepatic bile ducts contain several transport systems for their secretory and absorptive functions, 2 including the anion exchanger 2 (AE2), the cystic fibrosis transmembrane conductance regulator (CFTR), which drives Cl -channel Cl -/HCO 3 -exchange via AE2, 38 and the apical Na + -dependent bile salt transporter (ASBT), which is involved in the reabsorption of bile salts. 39, 40 
GENETIC DISORDERS CAUSING CHOLESTATIC LIVER DISEASES
Mutations of transporter genes can result in hereditary cholestasis (Table 1) . 5, 7, Although these syndromes are rare, they provide excellent insights into the physiology of bile secretion and the pathophysiology of cholestasis. Progressive familial intrahepatic cholestasis (PFIC) is a severe type of cholestatic liver disease in infants. It progresses to liver cirrhosis before adolescence and is inherited in an autosomal recessive fashion. 42, 43 Therefore, only homozygotes or compound heterozygotes (carrying two different mutations of the same gene) develop the full clinical picture. Three types (PFIC 1-3) have been identified. PFIC-1 (Byler's disease) is characterized by low serum g-GT levels, normal serum cholesterol, elevated serum bile salts and low biliary bile salt levels. Benign recurrent intrahepatic cholestasis (BRIC; Summerskill-Walshe syndrome) is characterized by recurrent episodes of cholestasis in children or adults, which do not progress to liver cirrhosis. Both PFIC-1 and BRIC are caused by mutations of a gene encoding a 'P-type ATPase' (FIC1) likely to be involved in hepatic bile salt excretion and/or the enterohepatic circulation of bile salts. 35 The mutations were found in different regions of the FIC1 gene, possibly explaining the different phenotypic appearances of PFIC-1 and BRIC. Extrahepatic manifestations in both diseases (e.g. diarrhea, bile salt malabsorption, pancreatitis, nephrolithiasis) may be explained by extrahepatic expression of FIC1 and can persist after liver transplantation in patients with PFIC-1. 36 Greenland familial cholestasis (resembling PFIC-1) is also caused by a FIC1 mutation. 44 PFIC-2 is caused by mutations in the BSEP/SPGP gene 33 resulting in a defective or even completely absent canalicular bile salt export pump (BSEP) in the liver of these patients. 45 In contrast to PFIC-1, extrahepatic manifestations are typically absent since the genetic defect is restricted to the liver. In contrast to PFIC-1 and PFIC-2, the third subtype, PFIC-3, is characterized by high g-GT serum levels, the absence of lipoprotein X (an abnormal lipoprotein which is usually present in cholestatic liver diseases), as well as bile duct proliferation and inflammatory infiltrates in portal areas. 42, 43 This type of cholestasis is caused by mutations of the MDR3-gene encoding the canalicular phospholipid export pump and resulting in a marked reduction of biliary phospholipid (phosphatidylcholine) levels. 46 Since phospholipids in bile protect bile duct epithelial cells from bile salt toxicity by the formation of mixed micelles, the reduction or absence of biliary phospholipids may explain bile duct injury in these patients. The pathophysiological consequences and potential therapeutic approaches were originally discovered in Mdr2 (rodent homolog of human MDR3) (-/-) knockout mice in whom the absence of lipoprotein X suggests a role for MDR3/Mdr2 in the formation of this abnormal lipoprotein during cholestasis. 47 PFIC-3 provides an important link between a hepatocellular (canalicular) transport defect and the development of bile duct injury.
CYSTIC FIBROSIS
It is beyond the scope of this review to discuss cystic fibrosis (CF) in great detail. It should be stressed that the cystic fibrosis gene product, the cystic fibrosis transmembrane conductance regulator (CFTR) is a major regulator of cholangiocellular bile formation. Cystic fibrosis transmembrane conductance regulator is a cyclic adenosine monophosphate (cAMP) mediated Cl -channel, which has been identified in several epithelia including lung, biliary tract, pancreas, and vas deference. This wide distribution accounts for the multiorgan involvement seen in cystic fibrosis. The primary function of CFTR is chloride secretion, and failure of a cAMP-mediated chloride secretion is a feature of CF. At the cholangiocellular level, mutations of the CFTR gene may result in cholestasis in cystic fibrosis patients. 48 Later in life, hepatobiliary complications may occur and include cholestatic liver disease due to duct abnormalities and finally secondary biliary cirrhosis. The diagnostic criteria established by a consensus panel of the Cystic Fibrosis Foundation 49 require one or more characteristic phenotypic features and one of three laboratory findings: an elevated sweat chloride concentration on two occasions, the identification of two known CFTR mutations, and the demonstration of abnormal nasal epithelial ion transport.
HEPATOBILARY TRANSPORT SYSTEMS IN ACQUIRED CHOLESTASIS
Although hereditary cholestatic syndromes offer interesting new insights into biliary physiology and pathophysiology, they are rare and appear to be of limited clinical relevance. Far more important is the question whether hereditary transporter defects play a role in adult cholestatic liver diseases? A larger number of defects may be incomplete or mild, and may not become evident until later in adult life when these individuals are challenged with cholestatic agents. Furthermore, heterozygotes (which are unremarkable under basal conditions) may have an increased susceptibility to cholestatic injury (e.g. drugs, sex hormones). Heterozygosity for MDR3 mutations can be associated with intrahepatic cholestasis of pregnancy, as a result of a transient decompensation of the heterozygous state due to female sex hormones and their metabolites. 50 Therefore, hereditary transporter mutations may predetermine individual susceptibility to cholestatic liver injury and could explain the broad clinical spectrum of cholestatic liver diseases. In particular, genetic transporter defects or polymorphisms could play an important role in the pathogenesis of drug-induced cholestasis. 51 Inflammatory cytokines, oxidative stress and bile salts are major modulators of transporter expression during acquired forms of cholestasis, resulting in reduced expression and impaired function of transport proteins in extrahepatic biliary obstruction and inflammation-induced intrahepatic cholestasis (caused by sepsis, alcohol, drugs, etc.).
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HEPATIC COPPER TRANSPORT
Copper (Cu) is a micronutrient that plays an essential role in biology, serving as a cofactor for enzymes that modify neuropeptides, generate cellular energy, detoxify oxygen-derived radicals, mobilize iron, coagulate blood, and cross-link connective tissue (Table 2) . 52, 53 Genetic diseases including Menkes disease and Wilson disease underscore critical roles for Cu absorption and distribution. 54, 55 Recent studies in microorganisms and the characterization of the molecular basis of Cu-related genetic diseases have elucidated many of the components that orchestrate intracellular Cu metabolism. [53] [54] [55] [56] [57] [58] Dietary copper intake (about 1-4 mg/day) far exceeds the trace amounts required. Most of the ingested copper is taken up by the liver by an insaturable, carriermediated, energy independent mechanism (Fig. 3) . Cellular copper transport processes are required by all organisms for correct utilization in cell biochemical processes and avoidance of the toxicity of copper excess. 59 In the hepatocyte glutathione (GSH) has a affinity to Cu + and stable Cu + -GSH complexes are formed. Cu + -GSH function in the intracellular copper transport and is a effective copper donor to metallothionein and superoxyde dismutase. Metallothionein is a cytosolic, low molecular weight, cystein-rich, metal binding protein. The copper stored in metallothionein can be donated to other proteins, either following degradation in lysosomes or by exchange via GSHcomplexation. Cu is carried to subcellular compartments or Cu-dependent enzymes through the action of target-specific Cu chaperone proteins that include Atx1/Atox1, Cox17, and CCS. [56] [57] [58] 60, 61 Copper uptake and its distribution are critical processes to provide ade-quate Cu to a number of Cu-containing enzymes and proteins. The Atx1/Atox1 Cm chaperone directly interacts with the cytosolic Cu-binding domains of the Cutransporting P-type ATPases to provide Cu to the secretory compartment, where it is incorporated into ceruloplasmin. [61] [62] [63] [64] Copper is incorporated into apoceruloplasmin at the level of the Golgi compartment. Ceruloplasmin contains six tightly bound copper atoms. Its main function is to carry copper to various tissues and to act as ferrooxidase, converting Fe ++ to Fe +++ . 65, 66 In mammals, ceruloplasmin and hephaestin, multicopper ferroxidases in serum and in the intestine, respectively, have critical roles for iron homeostasis.The copper chaperone (CCS) directly interacts with apoCu, Zn superoxide dismutase (SOD) for the incorporation of Cu. 57 Mitochondrial Sco1 and Sco2 protein are involved in the incorporation of Cu delivered by Cox17 into cytochrome oxidase (COX) subunits. 68 Consistent with the role of Sco1 and Sco2 in Cu incorporation into COX, mutations in Sco1 or Sco2 genes have been identified from the characterization of the patients with COX deficiency.
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THE WILSON'S DISEASE GENE PRODUCT (ATP7B)
The Wilson protein (ATP7B) is localized in the transGolgi network and in cytoplasmic vesicles. 71 The functionally important regions of the Wilson's disease gene are six copper binding domains, a domain involved in the transduction of the energy of ATP hydrolysis to cation transport, a cation channel and phosphorylation domain, an ATP-binding domain and eight hydrophobic regions predicted to span the cell membrane. An important feature of this ATPase is the presence of a large N-terminal domain that contains six repeats of a copper-binding motif, which is thought to be responsible for binding this metal prior to its transport across the membrane. Copper is bound to the domain in Cu + form. X-ray absorption studies strongly suggest Cu + atoms are ligated to cysteine residues. Circular dichroism spectral analyzes suggest both secondary and tertiary structural changes upon copper binding to the domain. 72 These copper induced structural changes may sense different intracytoplasmic copper levels. At low copper concentration, copper is preferentially used for synthesis of copper containing proteins. At higher copper concentration conformational changes of ATP7B favor formation of lysosomal vesicles and increase biliary copper excretion. Thus, ATP7B may function as a intracellular copper sensor. This sensing function is impaired in patients carrying the most common mutation of ATP7B, H1069Q. This missense mutation occurs in 30-60% of patients of Eastern- 73 or Central-European origin. [74] [75] [76] This mutant protein has a 5-fold decrease in the half-life and lacks of detectable excretory function at 37°C. Its proper localization at the trans-Golgi network is restored at 28°C. This finding is comparable to the CFTR DF508 mutation, which properly refolds and bypasses the endoplasmic reticulum quality control machinery at lowered temperatures. 77 The H1069Q mutant was degraded by the proteasomes in the cytoplasm and formed aggresomes at the microtubule-organizing center similar to Mallory bodies on electron microscopy. 78 The misfolding and degradation of the H1069Q mutant protein may describe a more general model for WD in which various amino acid substitutions result in an abnormally folded protein that is rapidly degraded and hence non-functional. The loss of sensing function of the H1069Q ATP7B impairs biliary copper excretion but allows synthesis of holoceruloplasmin albeit at lower level. Other mutations were either extensively mislocalized (R778L) to the endoplasmic reticulum, or were localized normally but were unable to redistribute in response to copper (G943S). 79 Because hepatic uptake of dietary copper in not saturable, hepatic copper accumulation can easily be induced. Toxicity of copper, however, depends on its molecular association and subcellular localization rather than on its concentration in the liver. Metallothionein-bound copper is non-toxic. Several metals, including zinc, can induce metallothionein synthesis. Excess copper is secreted into the bile. There are at least three pathways for hepatobiliary excretion of copper:
80 lysosomal exocytosis, a GSH-dependent route at the canalicular membrane (probably by the mixed organic acid transporter c-MOAT) and secretion via ATP7B.
ROLE OF IMPAIRED COPPER HOMEOSTASIS BEYOND WILSON'S AND MENKES' DISEASE
Against the background that hepatic copper levels are regulated by highly sophisticated interplay of a variety of copper transporters to maintain normal Cu levels, 81 it will be important to determine whether functional impairments of these systems of Cu acquisition play a role in the initiation or progression of Cu-related diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, or transmissible spongiform encephalopathies. [82] [83] [84] Furthermore, it is tempting to assume that heterozygous carriers of one mutated Wilson's disease gene are at higher risk to suffer from hepatocellular oxidative injury elicited, that is by ethanol or drugs, than carriers of two fully functional genes. 85 
